Assessment of the Effectiveness, Socio-economic Impact and Implementation of a Digital Solution for Severe Patients (ADLIFE)

Integrated Personalized Care for Patients With Advanced Chronic Diseases to Improve Health and Quality of Life

ADLIFE is a EU-funded project developing innovative digital health solutions to support healthcare planning and care delivery for patients with advanced chronic conditions (chronic obstructive pulmonary disease and/or heart disease failure). ADLIFE's technology innovations will be deployed, used and evaluated in seven healthcare environments in Spain, the UK, Sweden, Germany, Denmark, and Israel.

ADLIFE intends to impact three stakeholders: patients, informal caregivers and health professionals, and consequently across the seven participating international healthcare systems. ADLIFE intervention aims at slowing down the patients' functional deterioration, ensuring their quality of life and promoting shared decision making, reducing the caregiver burden, and improving the health professional working conditions; all this under the scenario of an improvement in the healthcare resource use.

The research aims to prove whether the ADLIFE intervention can deliver appropriate targeted and timely care for patients with severe long-term diseases when applied in real-life settings. Based on a mixed-method approach, the study will provide scientific evidence based on the effectiveness, socio-economic, implementation and technology acceptance assessment of ADLIFE compared to the standard of care (SoC) to provide scientific evidence supporting the funding decision-making of the ADLIFE intervention.

Study Overview

• Status: Recruiting
• Conditions: Heart Failure NYHA Class III; Heart Failure NYHA Class IV; Chronic Obstructive Pulmonary Disease Severe
• Intervention / Treatment: Other: ADLIFE intervention

Detailed Description

The ADLIFE project (GA 875209) is funded by the EC and Co-ordinated by Kronikgune Institute for Health Services Research. The consortium is made up of a total of 12 partners, supplying technical, clinical & research expertise. These partners are based in the UK, Spain, Sweden, Denmark, Turkey, Israel, Poland, Belgium and Germany.

The research project ADLIFE aims to develop and implement innovative, personalised and digital solutions for the integrated healthcare of elderly people with advanced chronic diseases, especially for patients with COPD and/or chronic heart failure (www.adlifeproject.com). The digital solutions (ADLIFE toolbox) involves two interconnected platforms: the Patient Empowerment Platform (PEP), used by patients and informal caregivers and the Personalised Care Plan Management Platform (PCPMP) used by healthcare professionals. In addition, PCPMP includes a Service to assist clinical decision support (CDSS).

The work plan of the project is structured in three phases. The 1st phase addresses the Organizational issues and ICT platforms implementation. The 2nd phase focuses on the Intervention's large-scale deployment. ADLIFE intervention will be implemented in seven regions representing six different countries, involving patients, informal caregivers and healthcare professionals. The 3rd and last phase will conduct an evaluation where ADLIFE scientific question will be answered. The main research question is - "When applied in real-life settings, is the use of the ADLIFE toolbox able to deliver appropriate targeted and timely care for patients with Advanced Chronic Diseases?". Care will be considered appropriate when it is deployed at the time and in the way is needed in order to generate the best possible gain in health and quality of life. The scientific question reflects the complex innovation intervention and three complementary evaluation approaches will be used:

• An effectiveness assessment will be conducted to estimate the ADLIFE intervention impact compared to the Standard of care, applying mixed methods combining quantitative and qualitative analysis.
• A socio-economic impact assessment will estimate the long-term economic impact of the ADLIFE intervention compared to the Standard of care, applying a budget impact analysis based on simulation modelling.
• An implementation assessment will be performed under three different perspectives: the implementation of the research project itself will be assessed as well as the contextual factors that are relevant for the translation of the innovation action into routine practice and the acceptance of the technology and adoption evaluation.

The study is aiming to recruit a minimum of 846 patients, 1183 informal caregivers and 679 healthcare professionals to the ADLIFE pilot study across all seven pilot sites. in Basque Country (Osakidetza), United Kingdom (National Health Service Lanarkshire and University Hospital Coventry & Warwickshire - National Health Service Trust), Denmark (Odense University Hospital), Germany (Gesunder Werra-Meißner Kreis), Sweden (Region Jämtland Härjedalen) and Israel (Assuta Ashdod Hospital - Maccabi Healthcare Services Southern Region).

The ADLIFE intervention consists of the deployment and use of the ADLIFE toolbox by patients, informal caregivers and health professionals in the aforementioned pilot settings. The intervention starts in December 2022. The project envisages a three-month window from the start of the intervention to achieve the total number of patients recruited. During the study period, patients will have a personalised care plan, created in the ADLIFE toolbox, which will be developed and managed together with their healthcare professionals. The main task of patients and informal caregivers will be to use the ADLIFE toolbox as part of their healthcare process together with their healthcare professionals. All participants will be trained in the use of the platforms and their participation prior to the start of the study. The intervention will end in November 2023, after which the evaluation will be carried out to analyse the feasibility and benefits of the ADLIFE solution.

ADLIFE will comply with the data protection legislation of the European Union GDPR and additional legislation in each country on health care data and medical research. Informed consent to participate in the study will be obtained from intervention patients. The patients who are recruited will receive care and treatment using the ADLIFE system, will have identifiable data collected about them by healthcare professionals in PCPMP, and will use, and provide information about themselves, in the PEP system. In addition to the clinical data captured, the intervention group patients, their carers and the healthcare professionals involved in the project will participate in a series of system/project evaluations before and after the study.

A separate cohort of patients will be identified retrospectively from local health records at the end of the study to create a 'control' group. These patients will match the same inclusion criteria. However, this control group will have no active role in the study (they will follow the standard of care of their organization) and only their anonymised data will be utilized so that health-related outcomes, resource utilisation, medication use, etc., can be compared for the two groups over the same period.

Evaluation analyses will be carried out with control data and intervention data collected in each pilot site. The data for project evaluation purposes will only be available to the site from which the data originated, it will be kept within the healthcare provider infrastructure. For the evaluation process, these data will be coded protected in order to reduce risks. The healthcare utilisation and outcome data collected from intervention patients will be extracted from the ADLIFE system itself in a pseudonymised format. Data from control data will be collected from local health records systems in an anonymized format. The relevant individual-level data for study evaluation will be processed and will be sent to the evaluation partners to carry out the clinical evaluations of the ADLIFE solution.

• Study Type: Interventional
• Enrollment (Estimated): 846
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Dolores Verdoy; Phone Number: +34 944007797; Email: dverdoy@kronikgune.org

Study Locations

• Denmark
  • Region Of Southern Denmark
    • Odense, Region Of Southern Denmark, Denmark, 5000
      • Recruiting
      • Odense University Hospital
      • Contact: Anne Dichmann Sorknaes; Phone Number: +45 2447 8858; Email: anne.dichmann.sorknaes@rsyd.dk
• Germany
  • Hesse
    • Eschwege, Hesse, Germany, 37269
      • Active, not recruiting
      • Gesunder Werra-Meißner-Kreis GmbH
• Israel
  • Ashdod, Israel, 7744142
    • Recruiting
    • Maccabi Healthcare Services Southern Region
    • Contact: Rachelle Kaye; Phone Number: +972 (0)50 8800096; Email: rkkayer@gmail.com
    • Contact: Rachelle Kaye; Phone Number: +972 (0)50 8800096; Email: rachellek@assuta.co.il
  • Ashdod, Israel, 7747629
    • Recruiting
    • Assuta Ashdod Hospital
    • Contact: Rachelle Kaye; Phone Number: +972 (0)50 8800096; Email: rkkayer@gmail.com
    • Contact: Rachelle Kaye; Phone Number: +972 (0)50 8800096; Email: rachellek@assuta.co.il
• Spain
  • Araba
    • Vitoria-Gasteiz, Araba, Spain, 01006
      • Recruiting
      • Osakidetza
      • Contact: Dolores Verdoy; Phone Number: +34 944007797; Email: dverdoy@kronikgune.org
• Sweden
  • Jämtland
    • Ostersund, Jämtland, Sweden, 831 27
      • Withdrawn
      • Region Jämtland Härjedalen - RJH
• United Kingdom
  • Warwickshire
    • Coventry, Warwickshire, United Kingdom, CV2 2DX
      • Recruiting
      • University Hospitals Coventry and Warwickshire NHS Trust
      • Contact: Harpal Randeva; Phone Number: +44 24 7696 6238; Email: harpal.randeva@uhcw.nhs.uk

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 55 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

PATIENTS-Inclusion criteria

• Senior (over 55)
• Heart failure (NYHA III-IV) in functional stage III/IV according to the NYHA scale and stages C and D of the ACCF/AHA classification. Stable phase (at least two months without decompensation requiring hospital care)
• And/or COPD (FEV1<50), >2 GOLD scale, and/or mMRC ≥ 2 and/or CAT ≥ 10 and/or use of oxygen at home
• With or without comorbidities
• They are able to provide informed consent
• They still live and generally plan on living in their home for the intervention duration
• They or their informal caregivers are able to use digital technology, communication tools, and/or networks and have access to a computer, laptop, tablet or smartphone and wifi/internet connection.
• They or their informal caregivers understand, read and talk the native language.

INFORMAL CAREGIVERS- Inclusion criteria

The informal caregiver will be a person who provides occasional or regular support to the patient's needs. Caregivers are eligible if:

• The patients they care for meet the inclusion criteria
• They give consent to participate

HEALTHCARE PROFESSIONALS-Inclusion criteria

Healthcare professionals are eligible if they care for patients who meet the inclusion criteria and consent to participate. Healthcare professionals taking part in ADLIFE should be:

• involved in the selected patients' care.
• open to new ways of working, specifically as part of coordinative and collaborative teams.
• open to the use of new technology. They should be willing to learn how to use technology to support their work.

Exclusion Criteria:

PATIENTS-Exclusion criteria

Patients are not eligible for recruitment if:

• Presence of active malignant neoplastic disease.
• Inclusion in the active list of any kind of transplantation.
• No signature of Informed consent by a legally capable patient.
• Patients who have participated in ADLIFE and later have withdrawn from their participation in the study the intervention formally are not eligible for recruitment again.

INFORMAL CAREGIVERS-Exclusion criteria

-Caregivers are not eligible if the patients they care for meet the exclusion criteria.

HEALTHCARE PROFESSIONALS-Exclusion criteria

• Healthcare professionals are not eligible if they do not care for patients who meet the inclusion criteria or only care for patients who meet the exclusion criteria.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intervention group; Use of the ADLIFE system	Other: ADLIFE intervention; The ADLIFE toolbox will be deployed, used and evaluated in seven healthcare environments to demonstrate the effectiveness of the ADLIFE intervention in clinical real conditions. Patients participating in ADLIFE will have a personalised care plan, created in the ADLIFE toolbox, developed and managed together with their healthcare professionals. PCPMP will be used within clinical sites´ ICT systems to create patient care plans based on most recent clinical data, following clinical evidence. The main task of patients and informal caregivers will be to use the ADLIFE toolbox as part of their healthcare process together with their healthcare professionals. Patients recruited will use the ADLIFE system during the pilot study (a year). If the proposed sample size is not reached by the start date (Dec. 2022), the recruitment period could be expanded to a maximum of three additional months. Patient's follow-up may range between 9 (March-Nov. 2023) and 12 (Dec. 2022 - Nov. 2023) months.
No Intervention: Control group; Patients will receive the Standard of Care

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline patient visits to the emergency (ER) department at 12 months	Change from Baseline in the number of patient visits to the emergency (ER) department during a 12 month-period. Data collected from EHR.	The primary outcome will be observed 12 months after the baseline.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline Patient-Reported Outcome Measurements (PROMs) on health-related quality of life at 12 months	Outcome measure reported by patients by means of completion of the questionnaire EQ-5D-5L	The change in the health related quality of life of the patient measured by means of EQ-5D-5L will be observed for a period up to 12 months, starting from the baseline
Change from baseline PPatient-Reported Outcome Measurements (PROMs) on mood/emotional health at 12 months	Outcome measure reported by patients by means of completion of the questionnaire HADS-Hospital Anxiety and Depression Scale	The change in the mood/emotional health of patient measured by means of HADS-Hospital Anxiety and Depression Scale will be observed for a period up to 12 months, starting from the baseline.
Change from baseline Patient-Reported Outcome Measurements (PROMs) on the ability of patients to perform tasks that are required to live independently in the community measured by Lawton scale at 12 months	Outcome measure reported by patients by means of completion of the Lawton scale	The change on the ability of patients to perform tasks that are required to live independently in the community measured by means of Lawton scale will be observed for a period up to 12 months, starting from the baseline
Change from baseline capability of the patient to perform basic activities in daily life at 12 months.	Outcome measured reported by patients by means of answering of the Barthel Index	The change on the capability of the patient to perform basic activities in daily reflecting the ability to function independently life measured by means of Barthel index will be observed for a period up to 12 months, starting from the baseline
Change from baseline Patient-Reported Outcome Measurements (PROMs) on health status in patients with heart failure at 12 months	Outcome measure reported by patients by means of completion of the questionnaire Kansas City Cardiomyopathy Questionnaire score	The change on health status in patients measured by means Kansas City Cardiomyopathy Questionnaire score questionnaire will be observed for a period up to 12 months, starting from the baseline
Change from baseline Patient-Reported Outcome Measurements (PROMs) on the impact of COPD on the patients' health status at 12 months	Outcome measure reported by patients by means of completion of the questionnaire COPD assessment test score	The change on the impact of COPD on the patient's health status measured by means of COPD assessment test score will be observed for a period up to 12 month, starting from the baseline
Change from baseline Patient-Reported Outcome Measurements (PROMs) on complexity at 12 months.	Outcome measure reported by patients by means of completion of the Modified Medical Research Council -mMRC- Dyspnea Scale	The change on the complexity measured by means of Modified Medical Research Council -mMRC- Dyspnea Scale will be observed for a period up to 12 months, starting from the baseline
Resource use due to patient healthcare visits	Outcome measured by means of number and type of patient healthcare visits	Resource use of intervention patients will be measured during the 12-months before and after the baseline
Resource use due to number of patient hospital admissions	Outcome measured by means of the number of patient hospital admissions	Resource use of intervention patients will be measured during the 12-months before and after the baseline
Resource use due to duration of patient hospital admissions	Outcome measured by means of the number of the days of the patient hospital admissions	Resource use of intervention patients will be measured during the 12-months before and after the baseline
Associated costs to resource use due to number and type of patient healthcare visits	Outcome measured by cost of patient healthcare visits (considering the number, duration and the unit costs)	Resource use of intervention patients will be measured during the 12-months before and after the baseline
Associated costs to resource use due to patient hospital admissions	Outcome measured by cost of patient hospital admissions (taking into account the number, duration and the unit costs of hospitalisations)	Resource use of intervention patients will be measured during the 12-months before and after the baseline
Change from baseline burden of care of the informal caregivers at 12 months	Outcome measured by completion of Zarit Burden Interview, ZBI by the informal caregivers	The change on the Burden of care measured by means of Zarit Burden Interview will be observed for a period up to 12 months, starting from the baseline
Associated costs to drug prescription	Outcome measured by total drug prescription cost that patients have	Resource use of intervention patients will be measured during the 12-months before and after the baseline
Change from baseline mental well-being of informal caregivers at 12 months.	Outcome measured by completion of Warwick-Edinburgh Mental Wellbeing Scale, WEMWBS by the informal caregivers	The change on the Mental well-being of informal caregivers measured by means of of Warwick-Edinburgh Mental Wellbeing Scale will be will be observed for a period up to 12 months, starting from the baseline
Change from baseline Technology acceptance and future adoption of the ADLIFE intervention by ADLIFE participants (patients, informal caregivers and health care professionals) at 12 months	Outcome measured by completion of the Unified Theory of Acceptance and Use of Technology (UTAUT)	The change on the technology acceptance measured by means of the Unified Theory of Acceptance and Use of Technology will be observed for a period up to 12 months, starting from the baseline
Satisfaction with accessibility, security and Personalized Care Plans by ADLIFE participants (patients, informal caregivers and health care professionals)	Outcome measured by qualitative analyses (semi-structured interviews)	The satisfaction with accessibility, security and Personalized Care Plans measured by means of semi-structured interviews will be observed after 12 months from the baseline
Barriers/facilitators related to the implementation process, by ADLIFE participants (patients, informal caregivers and health care professionals)	Outcome measured by qualitative analyses (semi-structured interviews)	The change on the barriers/facilitators related to the implementation process measured by means of semi-structured interviews will be observed after 12 months from the baseline
Perceived coordination among settings by health care professionals	Outcome measured by qualitative analyses (semi-structured interviews)	The change on the perceived coordination among settings measured by means of semi-structured interviews will be observed after 12 months from the baseline
Quality of care related to integration of care, decision making process and working condition by health care professionals	Outcome measured by qualitative analyses (semi-structured interviews)	The change on the quality of care related to integration of care, decision making process and working condition measured by means of semi-structured interviews will be observed after 12 months from the baseline
Perceptions on healthcare visits and hospital admissions burden by health care professionals	Outcome measured by qualitative analyses (semi-structured interviews)	The change on the perceptions on healthcare visits and hospital admissions burden measured by means of semi-structured interviews will be observed after 12 months from the baseline
Implementation assessment by health care professionals, IT staff and clinical managers	Outcome measured by contextual factors focusing on local technological, organizational, and human factor (semi-structured interviews)	The change on the implementation assessment measured by means of semi-structured interviews will be observed after 12 months from the baseline.

Collaborators and Investigators

• Sponsor: Kronikgune
• Collaborators: Odense University Hospital; Assuta Ashdod Hospital; Maccabi Healthcare Services, Israel; Osakidetza; University Hospitals Coventry and Warwickshire NHS Trust; NHS Lanarkshire; Gesunder Werra-Meißner-Kreis GmbH
• Investigators: Study Chair: Esteban de Manuel, Instituto de Investigación en Servicios de Salud KRONIKGUNE

Study record dates

Study Major Dates

• Study Start (Actual): February 1, 2023
• Primary Completion (Estimated): May 31, 2024
• Study Completion (Estimated): June 30, 2024

Study Registration Dates

• First Submitted: September 22, 2022
• First Submitted That Met QC Criteria: October 10, 2022
• First Posted (Actual): October 12, 2022

Study Record Updates

• Last Update Posted (Actual): January 9, 2024
• Last Update Submitted That Met QC Criteria: January 7, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Keywords: Quality of life; Integrated care; Shared decision making; Early detection; Multimorbidity; Patient Reported Outcome Measures (PROMs); Personalized care; Advanced chronic conditions; NYHA III-IV; >2 GOLD Scale; Clinical decision support services; Patient and informal caregiver empowerment; Outcome-based care
• Additional Relevant MeSH Terms: Pathologic Processes; Heart Diseases; Cardiovascular Diseases; Respiratory Tract Diseases; Lung Diseases; Disease Attributes; Chronic Disease; Heart Failure; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive
• Other Study ID Numbers: 875209

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No